STING-mediated cancer immunotherapy: emerging modalities and beyond.
Controlled, pulsatile STING activation rather than sustained activation shows promise to unleash stronger anti-tumor immunity in laboratory models.
This Trends in Pharmacological Sciences review critically analyzes why STING agonist cancer immunotherapy has underperformed clinically, attributing failures to uncontrolled sustained activation causing immune exhaustion rather than productive anti-tumor immunity. Novel delivery strategies including stimuli-responsive, biomimetic, and pulsatile systems that enable precise spatiotemporal STING activation are reviewed as promising solutions to improve clinical translation.
What the study was
- Study design
- Narrative review
- Population
- Review of preclinical and clinical STING agonist immunotherapy studies
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Trends in Pharmacological Sciences
Why it surfaced
High-impact review journal (Trends Pharmacol Sci); addresses clinically important STING agonist translation gap; useful contextual piece for T6 immunotherapy watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.